Prevalence and risks for bacterial vaginosis in women who have sex with women.

PubWeight™: 1.09‹?› | Rank: Top 10%

🔗 View Article (PMC 3291172)

Published in Sex Transm Dis on May 01, 2010

Authors

Jeanne M Marrazzo1, Katherine K Thomas, Kathy Agnew, Kathleen Ringwood

Author Affiliations

1: Department of Medicine, University of Washington, Seattle, USA. jmm2@u.washington.edu <jmm2@u.washington.edu>

Articles citing this

Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One (2010) 1.08

The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One (2013) 1.03

Emerging Sexual Health Issues Among Women Who Have Sex with Women. Curr Infect Dis Rep (2012) 1.02

Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis (2012) 1.00

Use of barrier protection for sexual activity among women who have sex with women. Int J Gynaecol Obstet (2012) 0.84

Evaluation of Association between Vaginal Infections and High-Risk Human Papillomavirus Types in Female Sex Workers in Spain. ISRN Obstet Gynecol (2012) 0.83

Effect of sexual activity on vaginal colonization with hydrogen peroxide-producing lactobacilli and Gardnerella vaginalis. Sex Transm Dis (2011) 0.82

Effect of sexual debut on vaginal microbiota in a cohort of young women. Obstet Gynecol (2012) 0.81

Characterization of the vaginal microbiota among sexual risk behavior groups of women with bacterial vaginosis. PLoS One (2013) 0.81

A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect (2011) 0.80

Women's Views and Experiences of the Triggers for Onset of Bacterial Vaginosis and Exacerbating Factors Associated with Recurrence. PLoS One (2016) 0.78

Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res (2016) 0.78

Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis (2016) 0.78

Factors Associated with Bacterial Vaginosis among Women Who Have Sex with Women: A Systematic Review. PLoS One (2015) 0.77

Molecular analysis of the relationship between specific vaginal bacteria and bacterial vaginosis metronidazole therapy failure. Eur J Clin Microbiol Infect Dis (2014) 0.76

Women's Management of Recurrent Bacterial Vaginosis and Experiences of Clinical Care: A Qualitative Study. PLoS One (2016) 0.76

Women view key sexual behaviours as the trigger for the onset and recurrence of bacterial vaginosis. PLoS One (2017) 0.75

A case control study of anovaginal distance and bacterial vaginosis. Int J STD AIDS (2011) 0.75

Articles cited by this

Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science (1998) 25.53

Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol (1991) 20.49

Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med (1983) 16.63

Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol (2000) 7.77

High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis (2006) 5.96

The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis (2007) 3.93

Application of computer-assisted interviews to sexual behavior research. Am J Epidemiol (1999) 3.82

Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis (2005) 3.50

Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol (2003) 3.36

Comparability of a computer-assisted versus written method for collecting health behavior information from adolescent patients. J Adolesc Health (1999) 2.58

Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol (2006) 2.56

A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis (2008) 2.09

Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09

Gynecologic conditions and bacterial vaginosis: implications for the non-pregnant patient. Infect Dis Obstet Gynecol (2000) 1.74

Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseases. Sex Transm Dis (2005) 1.56

Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception (2006) 1.52

Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol (2004) 1.20

Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex Transm Dis (2008) 1.16

Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis (2009) 1.03

A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe. Contraception (2007) 0.91

Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol (2009) 0.88

Vulvovaginal candidiasis in women who have sex with women. Sex Transm Dis (2008) 0.81

Articles by these authors

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23

Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med (2005) 3.96

Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol (2007) 3.10

Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One (2010) 2.62

Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44

Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol (2009) 2.29

HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis (2009) 2.23

Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18

Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09

Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis (2012) 1.67

Determinants of recent HIV infection among Seattle-area men who have sex with men. Am J Public Health (2008) 1.61

Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med (2008) 1.59

Using nurses to identify HAART eligible patients in the Republic of Mozambique: results of a time series analysis. Hum Resour Health (2007) 1.51

Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PLoS One (2011) 1.35

Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses (2010) 1.26

Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med (2014) 1.24

Identification and sequencing of bacterial rDNAs in culture-negative amniotic fluid from women in premature labor. Am J Perinatol (2004) 1.23

Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol (2004) 1.20

Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS (2013) 1.19

Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women. J Clin Microbiol (2010) 1.17

The relationship between racial identity, income, stress and C-reactive protein among parous women: implications for preterm birth disparity research. J Natl Med Assoc (2008) 1.14

Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr (2014) 1.09

Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One (2010) 1.08

Performance of a new, rapid assay for detection of Trichomonas vaginalis. J Clin Microbiol (2004) 1.05

Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis (2009) 1.03

Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters. AIDS Res Hum Retroviruses (2013) 1.02

Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett (2010) 1.01

Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis (2012) 1.00

An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda. J Acquir Immune Defic Syndr (2014) 0.98

Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. AIDS (2015) 0.97

Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother (2012) 0.90

Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora. Am J Obstet Gynecol (2002) 0.90

Expedited partner therapy: a robust intervention. Sex Transm Dis (2010) 0.88

Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: a randomized clinical trial. Sex Transm Dis (2011) 0.86

Changes in the vaginal microenvironment with metronidazole treatment for bacterial vaginosis in early pregnancy. J Womens Health (Larchmt) (2009) 0.83

Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy. J Clin Endocrinol Metab (2007) 0.83

Effect of sexual activity on vaginal colonization with hydrogen peroxide-producing lactobacilli and Gardnerella vaginalis. Sex Transm Dis (2011) 0.82

Cervical shedding of human T cell lymphotropic virus type I is associated with cervicitis. J Infect Dis (2002) 0.82

Effects of pregnancy and bacterial vaginosis on proinflammatory cytokine and secretory leukocyte protease inhibitor concentrations in vaginal secretions. J Pregnancy (2010) 0.81

Chlamydia positivity in women screened in family planning clinics: racial/ethnic differences and trends in the northwest U.S., 1997-2006. Public Health Rep (2012) 0.81

A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect (2011) 0.80

Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. AIDS (2016) 0.78

Variation in microbiologic profiles among pregnant women with bacterial vaginosis. Am J Obstet Gynecol (2005) 0.77

Detection of hydrogen peroxide-producing Lactobacillus species in the vagina: a comparison of culture and quantitative PCR among HIV-1 seropositive women. BMC Infect Dis (2012) 0.77

Vaginal and Rectal Clostridium sordellii and Clostridium perfringens Presence Among Women in the United States. Obstet Gynecol (2016) 0.76

Hydrogen Peroxide-Producing Lactobacilli Are Associated With Lower Levels of Vaginal Interleukin-1β, Independent of Bacterial Vaginosis. Sex Transm Dis (2015) 0.76

Effect of the levonorgestrel intrauterine device on genital HIV-1 RNA shedding among HIV-1-infected women not taking antiretroviral therapy in Nairobi, Kenya. J Acquir Immune Defic Syndr (2013) 0.76

Anti-HE4 antibodies in infertile women and women with ovarian cancer. Gynecol Oncol (2013) 0.76

Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data. J Acquir Immune Defic Syndr (2017) 0.75

Antiretroviral Therapy Initiation Is Not Associated With Risky Sexual Behavior Among Heterosexual Human Immunodeficiency Virus-Infected Persons in Serodiscordant Partnerships. Sex Transm Dis (2017) 0.75

Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines. Sex Transm Dis (2016) 0.75

Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection. J Acquir Immune Defic Syndr (2016) 0.75

Safety, acceptability, and tolerability of 3 topical microbicides among heterosexual Kenyan men. J Acquir Immune Defic Syndr (2007) 0.75

Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy. Int J Gynecol Cancer (2016) 0.75